Neuland Laboratories Limited (NEULANDLAB) — Announcement | 10 August 2026

10 August 2026 · NSE Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Q1FY27 revenue up 16.3% YoY to INR650.1 crores

🔄 What Changed

Working capital days reduced from 137 to 84

🔮 What's Next

20% growth target for FY27 and FY28

💡 Investor Takeaway

Shareholders should note growth is anchored in complex modalities and capacity expansion, but revenue remains concentrated in a few key molecules.

⚠️ Risks

Geopolitical risks and inherent business volatility

Neuland Laboratories reported a 16.3% YoY revenue jump to INR650.1 crores in Q1FY27, driven by CMS projects, with EBITDA at INR231.1 crores (35.5% margin) and PAT at INR147.4 crores (EPS: INR114.9). Working capital days fell to 84 from 137, reflecting improved efficiency. Capex of INR121.6 crores was deployed on R&D and peptide facilities, while INR203 crores were approved for strategic growth, mainly capacity expansion at Unit 1. Management highlighted strong GDS and CMS performance, collaborations like Gland Pharma, and confidence in FY27 growth despite volatility and geopolitical risks.

📄 View Original Announcement (PDF)

📊 Stock Analysis — NEULANDLAB ✨ Ask AI About This

About Neuland Laboratories Limited (NEULANDLAB)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹27,498.49 CrP/E: 55.2ROE: 26.6%ROCE: 33.6%Div Yield: 0.16%

View full NEULANDLAB stock details →

📡 Get AI alerts when NEULANDLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track NEULANDLAB — Free

💡 Ask AI about this filing

"How will 20% growth target be achieved?""What is the timeline for peptide capacity utilization?""How will ROCE be managed during expansion?"

Ask AI Free →

📊 More NEULANDLAB filings

Announcement — 25 September 2026Neuland Laboratories has closed its insider trading window effective October 1, 2026, until 48 hours...
🔴 Announcement — 16 September 2026Neuland Laboratories announced its management will attend the Goldman Sachs Global Healthcare CDMO D...
🔴 Announcement — 15 September 2026Neuland Laboratories announced that its first commercial peptide manufacturing module is now operati...
🔴 Announcement — 9 September 2026Neuland Laboratories announced its management will attend three upcoming investor meetings in Septem...
🟡 Board Meeting — 7 September 2026Neuland Laboratories announced on September 7, 2026, that its board approved ₹126 crores capital exp...

See all NEULANDLAB filings →

🔥 Also filed on 10 August 2026

TIMKENTimken India LimitedFinancial Results DOMSDOMS Industries LimitedCorporate Action HGSHinduja Global Solutions LimitedFinancial Results SUNDRMFASTSundram Fasteners LimitedFinancial Results AMJLANDAmj Land Holdings LimitedAnnual Report KANSAINERKansai Nerolac Paints LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when NEULANDLAB files new disclosures

Track NEULANDLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.